Funded Startups in Wales
Among the 4 disclosed rounds in this Wales listing, Hexigone Inhibitors’ $2M Seed on 2026-06-02 dwarfs the next-largest disclosed amount ($1M for Virtue He…
Among the 4 disclosed rounds in this Wales listing, Hexigone Inhibitors’ $2M Seed on 2026-06-02 dwarfs the next-largest disclosed amount ($1M for Virtue Health Group on 2022-12-06), with the remaining disclosed rounds at $650K (Menna, 2024-09-10) and $100K (Everknock, 2022-01-13). That makes the largest disclosed round an outlier by size relative to the rest of the disclosed set.
Timing is clustered but with wide edges: rounds span 2022-01-13 to 2026-07-20, and 4 of the 7 most recent entries fall in 2024–2026 (e.g., Orvixo’s undisclosed pre-seed on 2026-07-20 and Hexigone Inhibitors on 2026-06-02), indicating more activity in the most recent years. The list is also concentrated geographically under the single city label “Wales” (7 of 7 entries), while sector coverage skews heavily to tech and life sciences (AI appears on Orvixo, Menna, and Awen Oncology; Health Care appears on Awen Oncology and Virtue Health Group), alongside multiple “Series Unknown” classifications (Polytag and Awen Oncology).
Most recent rounds
7 shownRelated listings
Frequently asked
Which is the largest disclosed round in this Wales set, and how much larger is it versus the rest?
Hexigone Inhibitors’ $2M Seed (2026-06-02) is the largest disclosed round, sitting above Virtue Health Group’s $1M Seed (2022-12-06). The other disclosed amounts are $650K (Menna, 2024-09-10) and $100K (Everknock, 2022-01-13).
Is there a temporal cluster among the most recent entries?
Yes. Four of the seven rows are dated in 2024–2026, including Orvixo (undisclosed, 2026-07-20) and Hexigone Inhibitors ($2M, 2026-06-02), with another dated 2024-09-10 (Menna, $650K). The oldest disclosed entry is Everknock at 2022-01-13 ($100K).
Do any sectors or themes recur enough to treat as a cluster for outreach?
Artificial Intelligence repeats in 3 entries: Orvixo (undisclosed, 2026-07-20), Menna ($650K, 2024-09-10), and Awen Oncology (2026-04-22, undisclosed) alongside broader life-science activity. Health Care also appears twice (Awen Oncology on 2026-04-22 and Virtue Health Group on 2022-12-06).
What stage mix dominates, and how often is the funding stage not specified?
“Series Unknown” appears twice (Awen Oncology on 2026-04-22 and Polytag on 2026-01-26), while Seed also appears twice (Hexigone Inhibitors on 2026-06-02 for $2M and Virtue Health Group on 2022-12-06 for $1M). The remaining named stages are Pre-Seed (Orvixo, undisclosed; Menna, $650K), plus Non-equity Assistance (Everknock, $100K).
Are there outliers in disclosed size that merit prioritizing?
The disclosed-size outlier is Hexigone Inhibitors at $2M (2026-06-02), which is substantially larger than the other disclosed rounds at $1M (Virtue Health Group), $650K (Menna), and $100K (Everknock). On the other side, the smallest disclosed amount is Everknock’s $100K Non-equity Assistance (2022-01-13).
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.